Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
REGENXBIO Inc. (Nasdaq: RGNX) generates frequent news as it advances a late-stage pipeline of adeno-associated virus (AAV) gene therapies for rare and retinal diseases. Company updates often focus on clinical trial progress for RGX-202 in Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for MPS II, RGX-111 for MPS I, and surabgene lomparvovec (ABBV-RGX-314, sura-vec) for wet age-related macular degeneration and diabetic retinopathy.
News releases highlight functional and biomarker data from ongoing studies, such as long-term North Star Ambulatory Assessment results in the AFFINITY DUCHENNE® trial of RGX-202 and analyses of cerebrospinal fluid biomarkers in MPS II. REGENXBIO also reports on pivotal trial enrollment milestones, including completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal trials for subretinal sura-vec in wet AMD and progress in the ALTITUDE® trial for diabetic retinopathy using suprachoroidal delivery.
Investors following RGNX news can also expect regular disclosures on regulatory interactions and key dates, such as the FDA’s extension of the Prescription Drug User Fee Act (PDUFA) action date for the RGX-121 Biologics License Application and anticipated timelines for pivotal data readouts and BLA submissions. The company’s collaboration and license activities with partners like AbbVie and Nippon Shinyaku, including amendments to development and milestone structures, are typically announced through press releases and corresponding Form 8-K filings.
In addition, REGENXBIO issues announcements about participation in major healthcare and investor conferences, where management presents clinical updates and strategic priorities. For a fuller picture of RGNX stock, readers can use this news feed to track clinical data presentations, manufacturing and commercial readiness updates, financial results press releases and other material events described in the company’s communications.
REGENXBIO Inc. (Nasdaq: RGNX) announced an agreement to sell a portion of its royalty rights from Novartis Gene Therapies' Zolgensma for $200 million. This transaction provides non-dilutive capital to enhance REGENXBIO's gene therapy pipeline and internal manufacturing capabilities. The agreement includes an upfront payment with future royalty potential, capped at 1.3 times the purchase price until November 2024. Zolgensma is approved in multiple countries for Spinal Muscular Atrophy (SMA) treatment, marking a significant milestone in gene therapy.
REGENXBIO (Nasdaq: RGNX) announced that the first patient has been dosed in its ALTITUDE Phase II trial for RGX-314, aimed at treating diabetic retinopathy (DR) via suprachoroidal delivery. This trial evaluates RGX-314's efficacy and safety, potentially providing a one-time treatment option to replace frequent anti-VEGF injections. The study plans to enroll about 40 patients, comparing RGX-314 with an observational control. Initial data is expected in 2021. DR, a leading cause of vision loss in adults, affects approximately 8 million in the U.S.
REGENXBIO Inc. (Nasdaq: RGNX) reported positive interim data from Cohorts 1 and 2 of its Phase I/II trial for RGX-121, a gene therapy targeting Mucopolysaccharidosis Type II (MPS II) in patients up to 5 years old. As of November 13, 2020, RGX-121 showed a good safety profile with no serious adverse events in 8 patients. Notable reductions in heparan sulfate levels in CSF were observed, and neurocognitive development continued in Cohort 1 patients. REGENXBIO plans to initiate Cohort 3 with a higher dose in Q1 2021, with more data to be presented at the WORLD Symposium in early 2021.
REGENXBIO (Nasdaq: RGNX) announced the dosing of the first patient in the Phase I/II trial for RGX-111, targeting Mucopolysaccharidosis Type I (MPS I). This investigational gene therapy aims to deliver the IDUA gene to the central nervous system using the NAV AAV9 vector. MPS I is a rare genetic disorder affecting 1 in 100,000 births, leading to severe neurological symptoms. The trial, focused on safety and pharmacodynamics, will enroll up to five patients, marking a significant step in REGENXBIO's commitment to treating rare diseases, following its previous candidate RGX-121.
REGENXBIO Inc. (Nasdaq: RGNX) announced participation in two upcoming virtual investor conferences in December 2020. The company will host a pre-recorded fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference and a live webcast at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 11:45 a.m. ET. The pre-recorded chat is now available on REGENXBIO's website for 30 days. REGENXBIO focuses on gene therapy through its proprietary NAV Technology Platform, featuring over 100 AAV vectors for various therapeutic applications.
REGENXBIO Inc. (Nasdaq: RGNX) announced two oral presentations at the AAO 2020 Annual Meeting (Nov 13-15) focused on their gene therapy for wet AMD. The first presentation will highlight the RGX-314 Phase I/II trial results, presented by Dr. Dante Pieramici. The second presentation, by Dr. Peter Campochiaro, will cover preclinical studies on suprachoroidal delivery of RGX-314. REGENXBIO aims to leverage its NAV Technology Platform for advancing gene therapy solutions across various therapeutic areas.
REGENXBIO Inc. (Nasdaq: RGNX) announces participation in upcoming virtual investor conferences. Key events include the 29th Annual Credit Suisse Virtual Healthcare Conference on November 12, 2020, at 8:45 a.m. ET, and the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 2:00 p.m. ET. Live webcasts will be available on REGENXBIO's website, with archived replays accessible for approximately 30 days post-presentation. The company focuses on gene therapy and has a broad pipeline utilizing its proprietary NAV Technology Platform.
REGENXBIO Inc. (RGNX) announced its Q3 2020 financial results, highlighting a significant revenue increase to $98.9 million, driven by Zolgensma royalties and an $80 million milestone payment. The company reported a net income of $8.8 million, reversing a loss from the previous year. Operational achievements include the initiation of Phase II trials for RGX-314 targeting wet AMD and diabetic retinopathy. Additionally, RGX-121's program expansion for MPS II patients was noted. Cash and equivalents stood at $289.8 million, ensuring funding through mid-2022.
REGENXBIO (Nasdaq: RGNX) will host a conference call on November 4, 2020, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020. The company aims to enhance lives through gene therapy using its proprietary NAV Technology Platform. Investors can access the call by phone or through a webcast available for 30 days. The platform includes over 100 novel AAV vectors, showcasing the company's commitment to developing a diverse pipeline of gene therapy candidates.
REGENXBIO Inc. (Nasdaq: RGNX) announced it will receive an $80 million milestone payment from Novartis AG due to Zolgensma achieving $1 billion in net sales. This revenue is expected to be recognized in Q3 2020. Zolgensma, a transformative gene therapy for spinal muscular atrophy, has positively impacted over 700 patients. Since its FDA approval in May 2019, REGENXBIO has received over $140 million from related royalties and milestones.
FAQ
What is the current stock price of Regenxbio (RGNX)?
What is the market cap of Regenxbio (RGNX)?
